JP Morgan Chase
ABCL icon

JP Morgan Chase’s AbCellera Biologics ABCL Stock Holding History

JP Morgan Chase’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177K Sell
21,851
-55,767
-72% -$273K ﹤0.01% 5683
2026
Q1 		$255K Buy
77,618
+4
+0% +$14 ﹤0.01% 5356
2025
Q4 		$265K Sell
77,614
-53,050
-41% -$237K ﹤0.01% 5381
2025
Q3 		$657K Sell
130,664
-4,777
-4% -$21.1K ﹤0.01% 4866
2025
Q2 		$465K Sell
135,441
-68,812
-34% -$171K ﹤0.01% 4822
2025
Q1 		$455K Sell
204,253
-76,780
-27% -$220K ﹤0.01% 4842
2024
Q4 		$823K Sell
281,033
-74,714
-21% -$208K ﹤0.01% 4760
2024
Q3 		$925K Buy
355,747
+21,483
+6% +$59.5K ﹤0.01% 4514
2024
Q2 		$989K Sell
334,264
-36,501
-10% -$138K ﹤0.01% 4288
2024
Q1 		$1.68M Sell
370,765
-38,494
-9% -$196K ﹤0.01% 3982
2023
Q4 		$2.34M Sell
409,259
-127,035
-24% -$589K ﹤0.01% 3715
2023
Q3 		$2.47M Buy
536,294
+61,563
+13% +$375K ﹤0.01% 3405
2023
Q2 		$3.07M Sell
474,731
-236,555
-33% -$1.61M ﹤0.01% 3234
2023
Q1 		$5.36M Buy
711,286
+118,102
+20% +$1.07M ﹤0.01% 2761
2022
Q4 		$6.01M Buy
593,184
+93,054
+19% +$1.07M ﹤0.01% 2675
2022
Q3 		$4.95M Buy
500,130
+90,026
+22% +$988K ﹤0.01% 2748
2022
Q2 		$4.37M Buy
410,104
+259,222
+172% +$2.19M ﹤0.01% 2895
2022
Q1 		$1.47M Buy
150,882
+68,844
+84% +$652K ﹤0.01% 3994
2021
Q4 		$1.17M Buy
+82,038
New +$1.24M ﹤0.01% 4265

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

JP Morgan Chase's ABCL Position: Q2 2026 in Review

JP Morgan Chase reduced its AbCellera Biologics (ABCL) stake by 72% in Q2 2026, selling an estimated $273K and leaving 21,851 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #5683.

JP Morgan Chase first reported a position in ABCL in Q4 2021 and has held it in 19 quarters since. The position peaked at $6.01M in Q4 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • JP Morgan Chase held 21,851 shares of AbCellera Biologics worth $177K as of Q2 2026.
  • JP Morgan Chase sold 55,767 AbCellera Biologics shares in Q2 2026, an estimated $273K.
  • AbCellera Biologics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5683 holding.
  • JP Morgan Chase first reported a position in AbCellera Biologics in Q4 2021 and has held it in 19 quarters since.
  • JP Morgan Chase's AbCellera Biologics position peaked at $6.01M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.